The First Registry. Comparison of anticoagulant treatment in
patients with atrial fibrillation

J 2014

The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation

ŠPINAR, Jindřich; Jiří VÍTOVEC; Miroslav SOUČEK; Lenka ŠPINAROVÁ; Růžena LÁBROVÁ et. al.

Základní údaje

Originální název

The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation

Autoři

ŠPINAR, Jindřich (203 Česká republika, garant, domácí); Jiří VÍTOVEC (203 Česká republika, domácí); Miroslav SOUČEK (203 Česká republika, domácí); Lenka ŠPINAROVÁ (203 Česká republika, domácí); Růžena LÁBROVÁ (203 Česká republika, domácí); Martina ŠIŠÁKOVÁ (203 Česká republika, domácí); Jiří JARKOVSKÝ (203 Česká republika, domácí); Jiří ŠPÁC (203 Česká republika, domácí) a Alena ONDREJKOVÁ (703 Slovensko, domácí)

Vydání

Experimental and Clinical Cardiology, Ontario, Pulsus Group, 2014, 1205-6626

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Kanada

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.758 v roce 2013

Kód RIV

RIV/00216224:14110/14:00076143

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Atrial fibrillation; Bleeding; Dabigatran; Risk; Warfarin

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 8. 2014 14:54, Soňa Böhmová

Anotace

V originále

Aim: The FIRST registry aimed to compare patients with atrial fibrillation treated with dabigatran or warfarin. Methods: The study was performed in 10 centres in the Czech Republic. Results: Upon enrolment, 33.2% and 35.6% of patients respectively showed sinus rhythm. The last dose of warfarin before changing to dabigatran was higher than the maintenance dose 6.4 ± 4.3 mg vs. 4.6 ± 3.2 mg (p < 0.001). The patients did not differ in the CHA2DS2-VASc score. The principal difference was in the HAS BLED score: 55.3% of patients treated with dabigatran demonstrated a score of three or more while only 33.5% of those treated with warfarin did (p < 0.001). In 14.7% of patients treated with dabigatran, serious bleeding was observed during the previous treatment with warfarin. In patients treated with warfarin serious bleeding occurred in 2.0%. The most frequent reason (56.6%) for changing over to dabigatran was the impossibility to maintain INR within the therapeutic range. Conclusion: Patients are transferred from warfarin to dabigatran in particular due to the impossibility to maintain INR within the therapeutic range, and these are more frequently patients with a higher bleeding risk.

Citovat

ŠPINAR, Jindřich; Jiří VÍTOVEC; Miroslav SOUČEK; Lenka ŠPINAROVÁ; Růžena LÁBROVÁ; Martina ŠIŠÁKOVÁ; Jiří JARKOVSKÝ; Jiří ŠPÁC a Alena ONDREJKOVÁ. The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation. Experimental and Clinical Cardiology. Ontario: Pulsus Group, 2014, roč. 20, č. 1, s. 662-673. ISSN 1205-6626.

@article{1194852,
   author = {Špinar, Jindřich and Vítovec, Jiří and Souček, Miroslav and Špinarová, Lenka and Lábrová, Růžena and Šišáková, Martina and Jarkovský, Jiří and Špác, Jiří and Ondrejková, Alena},
   article_location = {Ontario},
   article_number = {1},
   keywords = {Atrial fibrillation; Bleeding; Dabigatran; Risk; Warfarin},
   language = {eng},
   issn = {1205-6626},
   journal = {Experimental and Clinical Cardiology},
   title = {The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation},
   volume = {20},
   year = {2014}
}

TY  - JOUR
ID  - 1194852
AU  - Špinar, Jindřich - Vítovec, Jiří - Souček, Miroslav - Špinarová, Lenka - Lábrová, Růžena - Šišáková, Martina - Jarkovský, Jiří - Špác, Jiří - Ondrejková, Alena
PY  - 2014
TI  - The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation
JF  - Experimental and Clinical Cardiology
VL  - 20
IS  - 1
SP  - 662-673
EP  - 662-673
PB  - Pulsus Group
SN  - 12056626
KW  - Atrial fibrillation
KW  - Bleeding
KW  - Dabigatran
KW  - Risk
KW  - Warfarin
N2  - Aim: The FIRST registry aimed to compare patients with atrial fibrillation treated with dabigatran or warfarin. Methods: The study was performed in 10 centres in the Czech Republic. Results: Upon enrolment, 33.2% and 35.6% of patients respectively showed sinus rhythm. The last dose of warfarin before changing to dabigatran was higher than the maintenance dose 6.4 ± 4.3 mg vs. 4.6 ± 3.2 mg (p < 0.001). The patients did not differ in the CHA2DS2-VASc score. The principal difference was in the HAS BLED score: 55.3% of patients treated with dabigatran demonstrated a score of three or more while only 33.5% of those treated with warfarin did (p < 0.001). In 14.7% of patients treated with dabigatran, serious bleeding was observed during the previous treatment with warfarin. In patients treated with warfarin serious bleeding occurred in 2.0%. The most frequent reason (56.6%) for changing over to dabigatran was the impossibility to maintain INR within the therapeutic range. Conclusion: Patients are transferred from warfarin to dabigatran in particular due to the impossibility to maintain INR within the therapeutic range, and these are more frequently patients with a higher bleeding risk.
ER  -

ŠPINAR, Jindřich; Jiří VÍTOVEC; Miroslav SOUČEK; Lenka ŠPINAROVÁ; Růžena LÁBROVÁ; Martina ŠIŠÁKOVÁ; Jiří JARKOVSKÝ; Jiří ŠPÁC a Alena ONDREJKOVÁ. The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation. \textit{Experimental and Clinical Cardiology}. Ontario: Pulsus Group, 2014, roč.~20, č.~1, s.~662-673. ISSN~1205-6626.

Přehled o publikaci